Aspirin daily dose

In general, treatment of the asthma underlying NSAlDs sensitivity should follow standard asthma guidelines. This type of asthma is often severe and frequently high doses of inhaled corticosteroids and daily doses of oral corticosteroids are necessary. A special treatment option is a chronic desensitization to aspirin [8]. Desensitization and aspirin maintenance is routinely used in some centers for treatment of chronic rhinusinusitis with nasal polyposis. It is the only available procedure which allows AIA patients with ischemic heart disease to use aspirin. During the state of desensitization to aspirin, not only aspirin but almost all strong NSAIDs are tolerated, so desensitization and NSAID maintenance could be used for treatment of rheumatic disease or chronic pain syndromes. 

Dipyridamole Peak plasma levels of dipyridamole are achieved approximately 2 hours after administration of a daily dose of 400 mg dipyridamole and aspirin combination (given as 200 mg twice daily). The peak plasma concentration at steady-state is approximately 1.98 mcg/mL and the steady-state trough concentration is approximately 0.53 mcg/mL. 

A daily dose of 83 mg of aspirin has been shown to significantly decrease the risk of heart disease in people over 40 years old, yet most people over 40 don t follow this regimen. Why ... 

Piroxicam Feldene Long half-life (45 hours] allows once-daily dosing may be somewhat better tolerated than aspirin. 

As discussed in Section 5.4.4, individuals consuming large quantities of antacid formulations, anti-ulcerative medications, buffered analgesics, or antidiarrheal medications are exposed to higher than background doses of aluminum in their diet. Lione (1985a) estimated that from 126 to 728 mg and 840 to 5,000 mg were possible daily doses of aluminum consumed in buffered aspirins for rheumatoid arthritis and antacid products, respectively. These doses are from 6 to 40 times and 42 to 250 times greater, respectively, than aluminum doses obtained from consumption of foods (20-24 mg/day). 

Q10 Yes, aspirin is used in the secondary prevention of a further stroke. Aspirin inhibits the cyclooxygenase (COX) enzyme responsible for producing thromboxane in platelets. Thromboxane is involved in platelet aggregation, an early step in blood coagulation. A low daily dose of aspirin (75 mg) inhibits thromboxane production, preventing platelet aggregation and blood clotting in arteries. 

Aspirin s permanent inactivation of the anucleate platelet is also responsible for the cumulative effect seen with repeated daily dosing below 100 mg (25). Daily administration of 30 to 50 mg of aspirin has been shown to lead to complete suppression of platelet thromboxane synthesis in 7 to 10 days (25, 30, 31). This, in turn, leads to inhibition of platelet aggregation and prolongation of the bleeding time, a clinical test often useful in identifying patients with platelet functional defects for further study and characterization (28,32). 

Based on current data, 80 to 160 mg of aspirin per day (1 -2 baby aspirin tablets) provides the maximal antithrombotic effect of the dmg. There is considerable in vitro and clinical evidence supporting the choice of a daily dose of 80 to 160 mg for the prevention of arterial thromboembolism in all high risk situations (4). 

Among the clinical indications for aspirin, the dose for prevention of stroke in patients following a transient ischemic attack or initial minor stroke is presently disputed, hi this respect, direct con iaiisons reveal no diiforences in efficacy between 300 mg and 1200 mg daily or between doses of 30 and 283 mg daily, though a small sample size was involved (60,61). h should also be noted that studies in which patients on larger aspirin doses were seen to do better also received another antiplatelet diug (62). 

Vhe prostaglandins mediate inflammation and pain. Aspirin is a universally used drug. The pain-relieving properties of the drug are a consequence of its inhibition of cyclooxygenase. Aspirin covalently reacts with the enzyme, inhibiting the first reaction catalyzed by the enzyme, oxygenation. Daily doses of aspirin... 

As nearly aU of the risks seem to be dose-related (SEDA-21, 96), there is a good prospect that an even lower daily dose of aspirin may offer advantages in antithrombotic prophylaxis without an increased risk of bleeding, but the results of further such studies are stiU awaited (9). 

Ibuprofen prolongs bleeding time, although less than aspirin (10). There are reports that a daily dose of less than 1 g does not affect the bleeding time (11). 

Kolodny AL, Klipper AR, Harris BK, et al. The efficacy and safety of single daily doses of oxaprozin in the treatment of osteoarthritis a comparison with aspirin. Semin Arthritis Rheum 1986 15 72. 

E Naproxen would be the reasonable choice because of the relatively infrequent (twice to three times daily) dosing regimen and more tolerable side effect profile compared with aspirin and indomethacin. Celecoxib and rofecoxib would be alternatives if the patient could not tolerate naproxen. These agents should be reserved for patients with known Gl bleeding disorders or intolerance to the other nonspecific NSAIDs. COX-2 inhibitors are still second-line therapy due to high cost and not well studied for the treatment of OA. 

---